$49.36 +0.14 (0.28%)

Hims & Hers Health, Inc. (HIMS)

Hims & Hers Health, Inc. is a telehealth company that offers a range of healthcare and wellness products and services. It provides virtual consultations, prescription medications, and over-the-counter wellness products across categories such as mental health, dermatology, sexual health, and primary care, aiming to improve access and convenience in healthcare delivery.

🚫 Hims & Hers Health, Inc. does not pay dividends

Company News

Should Investors Buy UnitedHealth Stock Instead of Hims & Hers Stock?
The Motley Fool • Parkev Tatevosian, Cfa • October 14, 2025

The article compares two healthcare companies, UnitedHealth and Hims & Hers, as potential long-term investment options, highlighting their unique characteristics in the healthcare industry.

3 Healthcare Stocks Using AI to Drive Growth
Investing.com • Chris Markoch • September 30, 2025

The article explores three healthcare stocks leveraging artificial intelligence to improve efficiency, patient outcomes, and administrative processes in the medical sector, highlighting how AI is transforming healthcare delivery.

Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy
Benzinga • Vandana Singh • September 16, 2025

The FDA issued a warning letter to Hims & Hers Health for making misleading claims about its compounded semaglutide products, suggesting they are equivalent to FDA-approved drugs like Ozempic and Wegovy. The company must respond within 15 days or face potential legal actions.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - HIMS
GlobeNewswire Inc. • Pomerantz Llp • August 25, 2025

Pomerantz LLP filed a class action lawsuit against Hims & Hers Health, Inc. alleging securities fraud after Novo Nordisk terminated their partnership due to concerns about deceptive drug promotion and selling unauthorized compounded medications.

Hims & Hers (HIMS) Gains 45.8% in Three Months: What's Next?
Zacks Investment Research • Zacks Investment Research • August 5, 2024

Hims & Hers Health, Inc. (HIMS) has seen a 45.8% stock price increase in the past three months, outperforming the industry and broader market. The company's recent announcements, including the addition of GLP-1 injections to its weight loss portfolio and positive 2024 revenue outlook, have contributed to the stock's upward momentum.